Objective  To explore and sort out the current situation and development process of individualized dosing in China, and to reveal its research hotspots and evolution trends.

Methods  The databases of CNKI, Wanfang, VIP, and Web of Science were searched for relevant literature on individualized dosing in China, from the inception of the databases to May 31, 2025.  Microsoft Office Excel 2021 was used to analyze the annual publication volume, publication trends, and journal distribution. VOSviewer 1.6.18 and CiteSpace 6.3R2 were employed to visualize the collaboration patterns of research entities and present keyword analysis results, respectively, thereby elucidating the current research status and key hotspots in individualized dosing.

Results   A total of 820 eligible research articles published in pharmaceutical related journals were ultimately included. The research in this field had roughly gone through three stages, with the highest number of publications in 2019 (61 articles). The cooperation among most scholars in this field was not close, and it mostly existed within their own institutions. The clinical application of individualized drug administration, related technologies, and drugs were the research focuses, but individualized drug administration of traditional Chinese medicine or traditional Chinese patent medicines and simple preparations was rarely involved. Utilizing new technologies and methods for individualized drug administration was a future research hotspot.

Conclusion  Since 2019, the academic interest and the number of research outcomes in the field of individualized dosing in China have both seen a decline to some extent compared to previous years. In the future, it is necessary to strengthen cross-regional and cross-institutional academic exchanges, promptly share the latest research results, and jointly promote the high-quality and in-depth development of individualized drug administration. Furthermore, efforts should be made to actively explore individualized dosing models suitable for traditional Chinese medicine or traditional Chinese patent medicines and simple preparations, and to meet the clinical needs for individualized dosing.

1.Moran S, Martinez-Cardús A, Boussios S, et al. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary[J]. Na Rev Clin Oncol, 2017, 14(11): 682-694. DOI: 10.1038/nrclinonc.2017.97.

2.李诗然, 李鹏飞, 谢婧娴, 等. 个体化用药的基础研究和临床实践研究进展[J]. 中国临床药学杂志, 2024, 33(9): 713-720. [Li SR, Li PF, Xie JX, et al. Progress in basic research and clinical practice of individualized dosing[J]. Chinese Journal of Clinical Pharmacy, 2024, 33(9): 713-720.] DOI: 10.19577/j.1007-4406.2024.09.016.

3.Cai M, Zhou L, Gao D, et al. A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019[J]. Front Pharmacol, 2023, 14: 1022134. DOI: 10.3389/FPHAR.2023.1022134.

4.Bourgeois FT, Kesselheim AS. Promoting pediatric drug research and labeling-outcomes of legislation[J]. New Engl J Med, 2019, 381(9): 875-881. DOI: 10.1056/NEJMhle1901265.

5.Li X, Dong P, Liang J, et al. Global trends and hotspots in esketamine research: a bibliometric analysis of past and estimation of future trends[J]. Drug Des Dev Ther, 2022: 1131-1142. DOI: 10.2147/DDDT.S356284.

6.陈悦, 陈超美, 胡志刚, 等, 主编. 引文空间分析原理与应用: CiteSpace实用指南[M]. 北京: 科学出版社, 2014: 69.

7.姚明, 康吉云, 李昊洋, 等. 我国药学监护领域研究现状及趋势的可视化分析[J]. 数理医药学杂志, 2025, 38(1): 16-26. [Yao  M, Kang JY, Li HY, et al. Visual analysis of the current research status and trends in the field of pharmaceutical care in China[J]. Journal of Mathematical Medicine, 2025, 38(1): 16-26.] DOI: 10.12173/j.issn.1004-4337.202409024.

8.Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial[J]. Ann Oncol, 2021, 32(4): 512-521. DOI: 10.1016/j.annonc.2020.12.018.

9.何志超, 伍俊妍, 邱凯锋. 万古霉素个体化给药临床药师指引[J]. 今日药学, 2015, 25(2): 78-82. [He ZC, Wu JY, Qiu  KF. Guidelines for clinical pharmacists on individualized dosing of vancomycin[J]. Pharmacy Today, 2015, 25(2): 78-82.] https://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_guangdyx201502004&dbid=WF_QK.

10.Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Ther Drug Monit, 2018, 40(6): 663-674. DOI: 10.1097/FTD.0000000000000561.

11.陈恳, 张相林, 克晓燕, 等. 《伏立康唑个体化用药指南》解读[J]. 临床药物治疗杂志, 2019, 17(3): 47-52, 78. [Chen  K, Zhang XL, Ke XY, et al. Executive summary of the practice guideline for individualized medication of voriconazole[J]. Clinical Medication Journal, 2019, 17(3): 47-52, 78.] DOI: 10.3969/j.issn.1672-3384.2019.03.012.

12.钟诗龙, 韩雅玲, 陈纪言, 等. 氯吡格雷抗血小板治疗个体化用药基因型检测指南解读[J]. 中国实用内科杂志, 2015, 35(1): 38-41. [Zhong SL, Han YL, Chen JY, et al. Nterpretation of clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy : 2013 update[J]. Chinese Journal of Practical Internal Medicine, 2015, 35(1): 38-41.] DOI: 10.7504/nk2014120302.

13.原曼, 尹安春, 梁战华, 等. 基于信息-动机-行为技巧模型的个体化用药管理方案在帕金森病患者中的应用[J]. 中国护理管理, 2018, 18(2): 179-184. [Yuan M, Yin AC, Liang ZH, et al. Application and evaluation of individualized drug management based on IMB model in patients with Parkinson's disease[J]. Chinese Nursing Management, 2018, 18(2): 179-184.] DOI: 10.3969/j.issn.1672-1756.2018.02.009.

14.陈珲, 蔡泓敏, 冯端浩, 等. CYP2C9和CYP2C19基因多态性对药物代谢的影响及个体化用药研究进展[J]. 中国药物应用与监测, 2014, 11(4): 240-244. [Chen H, Cai HM, Feng DH, et al. The progress of CYP2C9 and CYP2C19 genetic polymorphisms on drug metabolism and individualized drug therapy[J]. Chinese Journal of Drug Application and Monitoring, 2014, 11(4): 240-244.] https://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_zgywyyyjc201404017&dbid=WF_QK.

15.Zhao L, Chen J, Bai B, et al. Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing[J]. Front Pharmacol, 2024, 14: 1333986. DOI: 10.3389/fphar.2023.1333986.

16.高玉成, 焦正, 黄虹, 等. 万古霉素个体化给药决策支持系统的研制[J]. 药学学报, 2018, 53(1): 104-110. [Gao YC, Jiao Z, Huang H, et al. Development of decision system for individualization of vancomycin dosage[J]. Acta Pharmaceutica Sinica, 2018, 53(1): 104-110.] DOI: 10.16438/j.0513-4870.2017-0673.

17.Chen Y, Guo W, Lu Y, et al. Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy[J]. Radiother Oncol, 2008, 88(3): 351-358. DOI: 10.1016/j.radonc.2008.07.013.

18.陈文瑛, 黄思琪, 谢白露, 等. 伏立康唑个体化给药研究新进展[J]. 中国医院药学杂志, 2013, 33(14): 1181-1184. [Chen WY, Huang SQ, Xie BL, et al. Research progress of voriconazole individualized dosing[J]. Chinese Journal of Hospital Pharmacy, 2013, 33(14): 1181-1184.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2013.14.029.

19.陈晨, 张晏洁, 贺小露, 等. 他克莫司个体化用药指南解读[J]. 医学研究生学报, 2017, 30(4): 342-347. [Chen  C, Zhang YJ, He  XL, et al. Interpretation of tacrolimus guidelines for individualized medication[J]. Journal of Medical Research & Combat Trauma Care, 2017, 30(4): 342-347.] DOI: 10.16571/j.cnki.1008-8199.2017.04.002.

20.彭娟, 谭胜蓝, 周宏灏, 等. 华法林药物基因组学和个体化用药[J]. 中国药理学通报, 2013, 29(2): 169-172. [Peng J, Tan SL, Zhou HH, et al. Pharmacogenomics of warfarin and its personalized treatment[J]. Chinese Pharmacological Bulletin, 2013, 29(2): 169-172.] DOI: 10.3969/j.issn.1001-1978.2013.02.06.

21.王晓晨, 王思箭, 刘林夕, 等. 伏立康唑个体化给药研究进展 [J]. 中国抗生素杂志, 2020, 45(1): 16-25. [Wang XC, Wang  SJ, Liu LX, et al. Advances in individualized administration of voriconazole[J]. Chinese Journal of Antibiotics, 2020, 45(1): 16-25.] DOI: 10.13461/j.cnki.cja.006764.

22.倪伟建, 方焱, 张善堂, 等. 基于药物基因组学与血药浓度监测指导的个体化用药研究[J]. 中国医院药学杂志, 2018, 38(17): 1863-1868. [Ni WJ, Fang Y, Zhang ST, et al. Research progress of personalized medicine based on the pharmacogenomics and blood drug concentration monitoring[J]. Chinese Journal of Hospital Pharmacy, 2018, 38(17): 1863-1868.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.17.20.

23.严非, 夏春华, 熊玉卿. CYP2C19基因多态性对药物代谢的影响及其个体化用药[J]. 中国临床药理学与治疗学, 2010, 15(8): 949-953. [Yan F, Xia CH, Xiong YQ. Effect of CYP2C19 genetic polymorphism on drug metabolism and individualized therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 949-953.] https://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_zglcylxyzlx201008023&dbid=WF_QK.

24.徐晓涵, 陈恳, 孙浩, 等. 真菌感染患者对伏立康唑个体化用药的意愿调查[J]. 中国临床药理学杂志, 2017, 33(5): 456-458, 466. [Xu XH, Chen K, Sun H, et al. Investigation of willingness in individualized medication of voriconazole in fungal infectious patients[J]. The Chinese Journal of Clinical Pharmacology, 2017, 33(5): 456-458, 466.] DOI: 10.13699/j.cnki.1001-6821.2017.05.019.

25.陈恳, 梁舒瑶, 闫盈盈, 等. 用德尔菲法确定伏立康唑个体化用药指南临床问题与结局指标[J]. 中国临床药理学杂志, 2016, 32(4): 368-369, 381. [Chen K, Liang SY, Yan  YY, et al. Using Delphi method to determine the questions and outcomes included in the practice guidelines for individualized medication of voriconazole[J]. The Chinese Journal of Clinical Pharmacology, 2016, 32(4): 368-369, 381.] DOI: 10.13699/j.cnki.1001-6821.2016.04.028.

26.李若茗, 向倩, 胡琨, 等. SLCO1B1基因多态性的辛伐他汀个体化用药临床研究分析[J]. 中国临床药理学杂志, 2022, 38(14): 1688-1691. [Li RM, Xiang Q, Hu K, et al. Clinical study of simvastatin based on individual therapy based on SLCO1B1 gene polymorphisms[J]. The Chinese Journal of Clinical Pharmacology, 2022, 38(14): 1688-1691.] DOI: 10.13699/j.cnki.1001-6821.2022.14.025.

27.张晋萍, 葛卫红, 戴令娟. 临床药师参与呼吸科个体化给药方案设计的案例分析[J]. 中国药房, 2012, 23(2): 172-174. [Zhang JP, Ge WH, Dai LJ. Clinical pharmacists involving in individual dosage regimen design in respiratory department[J]. China Pharmacy, 2012, 23(2): 172-174.] DOI: 10.6039/j.issn.1001-0408.2012.02.30.

28.Li CJ, Li L. Tacrolimus in preventing transplant rejection in Chinese patients-optimizing use[J]. Drug Des Dev Ther, 2015: 473-485. DOI: 10.2147/DDDT.S41349.

29.王晓晨, 王思箭, 刘林夕, 等. 伏立康唑个体化给药研究进展 [J]. 中国抗生素杂志, 2020, 45(1): 16-25. [Wang XC, Wang  SJ, Liu LX, et al. Advances in individualized administration of voriconazole[J]. Chinese Journal of Antibiotics, 2020, 45(1): 16-25.] DOI: 10.3969/j.issn.1001-8689.2020.01.003.

30.孙丹, 岳宝森, 吕楠, 等. 基于替考拉宁游离药物浓度的个体化给药研究进展[J]. 中国感染与化疗杂志, 2025, 25(3): 334-339. [Sun D, Yue BS, Lyu N, et al. Research progress of individualized dosing based on free teicoplanin plasma concentration[J]. Chinese Journal of Infection and Chemotherapy, 2025, 25(3): 334-339. ] DOI: 10.16718/j.1009-7708.2025.03.014.

31.Hanai Y, Takahashi Y, Niwa T, et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J]. J Antimicrob Chemoth, 2022, 77(4): 869-879. DOI: 10.1093/jac/dkab499.

32.金锐, 郭红叶, 韩仙鸽, 等. 中成药处方审核的证据体系与通用规则构建研究[J]. 中南药学, 2022, 20(8): 1713-1720. [Jin R, Guo HY, Han XG, et al. Evidence system and general rule construction for Chinese patent medicineprescription review[J]. Central South Pharmacy, 2022, 20(8): 1713-1720.] DOI: 10.7539/j.issn.1672-2981.2022.08.001.

33.张淼, 陈婧婧, 曾力楠, 等. 中药治疗药物监测研究的系统评价[J]. 中国循证医学杂志, 2023, 23(1): 21-26. [Zhang  M, Chen JJ, Zeng LN, et al. Therapeutic drug monitoring for traditional Chinese medicine: a systematic review[J]. Chinese Journal of Evidence-Based Medicine, 2023, 23(1): 21-26.] DOI: 10.7507/1672-2531.202206020.

34.Damiani A, Caceres MDV, Roberts G, et al. A clinical practice-based comparison of conventional and individualized dosing strategies for therapeutic enoxaparin[J]. Pharmacol Res Perspe, 2025, 13(1): e70039. DOI: 10.1002/prp2.70039.

35.张华旭, 霍胜霞, 吴春兴. 治疗药物监测领域研究现状及趋势的文献计量学分析[J]. 数理医药学杂志, 2025, 38(5): 356-365. [Zhang HX, Huo SX, Wu CX. Bibliometric analysis of research status and trends in the field of therapeutic drug monitoring[J]. Journal of Mathematical Medicine, 2025, 38(5): 356-365.] DOI: 10.12173/j.issn.1004-4337.202502045.

36.Hassan R, Allali I, Agamah FE, et al. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine[J]. Brief Bioinform, 2021, 22(4): bbaa292. DOI: 10.1093/BIB/BBAA292.

37.李静, 郑伶利, 陈静, 等. 基因突变检测在个体化用药中的研究进展[J]. 现代药物与临床, 2018, 33(4): 1002-1008. [Li J, Zheng LL, Chen J, et al. Research progress on application of detection of gene mutation in individualized medication[J]. Drugs & Clinic, 2018, 33(4): 1002-1008.] DOI: 10.7501/j.issn.1674-5515.2018.04.060.

38.倪伟建, 方焱, 张善堂, 等. 基于药物基因组学与血药浓度监测指导的个体化用药研究[J]. 中国医院药学杂志, 2018, 38(17): 1863-1868. [Ni WJ, Fang Y, Zhang ST, et al. Research progress of personalized medicine based on the pharmacogenomics and blood drug concentration monitoring[J]. Chinese Journal of Hospital Pharmacy, 2018, 38(17): 1863-1868.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2018.17.20.